Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

NCT04435015 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT04435015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04435015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications
Lead sponsor
Yale University
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 30, 2021
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular complication, coagulopathy, covid-19